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Abstract
Sickle cell anemia (SCA) is an autosomal recessive monogenic disease with significant clinical variability. Cerebrovascular
disease, particularly ischemic stroke, is one of the most severe complications of SCA in children. This study aimed to investigate
the influence of genetic variants on the levels of fetal hemoglobin (Hb F) and biochemical parameters related with chronic
hemolysis, as well as on ischemic stroke risk, in ninety-one unrelated SCA patients, children of sub-Saharan progenitors. Our
results show that a higher Hb F level has an inverse relationship with the occurrence of stroke, since the group of patients who
suffered stroke presents a significantly lower mean Hb F level (5.34 ± 4.57% versus 9.36 ± 6.48%; p = 0.024). Furthermore, the
co-inheritance of alpha-thalassemia improves the chronic hemolytic pattern, evidenced by a decreased reticulocyte count (8.61 ±
3.58% versus 12.85 ± 4.71%; p < 0.001). In addition, our findings have confirmed the importance of HBG2 and BCL11A loci in
the regulation of Hb F expression in sub-Saharan African SCA patients, as rs7482144_A, rs11886868_C, and rs4671393_A
alleles are significantly associated with a considerable increase in Hb F levels (p = 0.019, p = 0.026, and p = 0.028, respectively).
ConcerningKLF1, twelve different variants were identified, two of them novel. Seventy-three patients (80.2%) presented at least
one variant in this gene. However, no correlation was observed between the presence of these variants and Hb F level, severity of
hemolysis, or stroke occurrence, which is consistent with their in silico-predicted minor functional consequences. Thus, we
conclude that the prevalence of functional KLF1 variants in a sub-Saharan African background does not seem to be relevant to
SCA clinical modulation.
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Introduction
Hemoglobinopathies are inherited anemia characterized by
abnormal structure, function, or amount of the globin chains
of hemoglobin. One of the most common hemoglobinopathies
worldwide, sickle cell anemia (SCA), is due to homozygosity
for the c.20A>T mutation in the beta-globin gene (HBB) that
gives rise to hemoglobin S (Hb S). Although SCA is a mono-
genic disease, it is clinically very heterogeneous due to the
influence of environmental and genetic modifiers, such as an
increased expression of fetal hemoglobin (Hb F) during adult
life [1–3]. The beneficial effect of higher levels of Hb F results
from the corresponding reduction of Hb S concentration in-
side the red blood cells thus hindering deoxy Hb S polymer-
ization [3]. Another known SCA clinical modifier is alpha-
thalassemia, a hemoglobinopathy due to reduced production
of alpha-globin chains. Its co-inheritance with SCA results in
a decreased intracellular concentration of Hb S and reduces
the likelihood and rate of Hb S polymerization [4, 5].
The Hb F level in normal adults is usually less than 1% of
the total hemoglobin. However, a variable level, ranging from
approximately 1 to 30%, is frequently observed among SCA
patients. A specific single nucleotide polymorphism (SNP)
within the beta-globin gene cluster on chromosome 11p15.5
partly accounts for this variation. It is the rs7482144 (the Xmn
I site) located in the promoter of the Gγ-globin gene (HBG2)
[6]. Furthermore, genome-wide association studies have iden-
tified two additional quantitative trait loci that affect baseline
Hb F levels in patients with hemoglobin disorders, which
involve the genetic determinants of trans-acting factors not
linked to the beta-globin cluster. They comprise the HBS1L-
MYB intergenic region on 6q22–23 and the BCL11A gene on
2p16.1 [7–12]. More recently, the trans-acting erythroid-spe-
cific Krüppel-like factor 1 (KLF1) was also implicated in Hb F
expression modulation. Additionally, KLF1 plays a multi-
functional role during erythropoiesis and is involved in the
activation of numerous erythroid genes, namely those
encoding globins, red cell membrane and structural proteins,
heme synthesis enzymes, and many other proteins involved in
red cell metabolism [13–16]. KLF1 modulates the fetal to
adult switching of hemoglobin by two ways: stimulating the
HBB gene expression through direct interaction with its pro-
moter, and repressingHBG gene expression indirectly through
the activation of its repressor BCL11A [17]. Therefore, it
seems that weakening the activity of KLF1 would stimulate
Hb F synthesis through the upregulation ofHBG gene expres-
sion. Accordingly, some KLF1 gene variants associated with
KLF1 haploinsufficiency have been related to higher Hb F
levels, which may be particularly relevant to some hemoglo-
binopathy clinical outcomes [14, 16, 18, 19]. Thus, it has been
hypothesized that KLF1 variants may have been under posi-
tive selection by malaria and this may justify their polymor-
phic frequencies in populations where some type of
hemoglobinopathies, such as beta-thalassemia and Hb E dis-
order, are commonly found, e.g., in Southern China and South
East Asia [19–21]. In contrast, the possible interaction of
KLF1 variants and SCA remains unclear. A study carried
out in a group of 44 SCA patients from India and the
Middle East did not replicate the previously described associ-
ation between KLF1 SNPs and Hb F level [22]. In addition,
studies performed on African Americans with SCA failed to
detect association between KLF1 SNPs and Hb F levels [23,
24]. In this regard, the lack of knowledge about the prevalence
of KLF1 variants and its contribution to Hb F levels and SCA
modulation is even greater when considering the African con-
text. A genome-wide association study performed in SCA
patients from an East African country (Tanzania) did not de-
tect an association between KLF1 SNPs and Hb F levels [25].
In accordance with those results, in a UK study where 55 SCA
patients were enrolled, only one Nigerian SCA patient pre-
sented a KLF1 functional variant [26]. Therefore, due to the
paucity of such data in African SCA populations, we screened
a group of sub-Saharan African SCA pediatric patients for
KLF1 gene variants. Apart from confirming the role of the
other known SCA genetic modifiers, we aimed to examine
the effect of KLF1 genetic variants on the phenotypic expres-
sion of Hb F in these patients, as well as in their
hematological/biochemical chronic hemolysis biomarkers
and cerebral vasculopathy outcome.
Materials and methods
Study population and data collection
Patients eligible for this study were unrelated children with
SCA, ≥ 3 years old, with a direct sub-Saharan African ances-
try, who had been followed up in general hospitals from the
Greater Lisbon area. Their genetic background is African;
however, many of these patients were born in Portugal.
After written informed consent given by the patients’ legal
representatives, ninety-one SCA children (3 to 16 years old)
were enrolled in this study (53 males and 38 females). All
participants are children of sub-Saharan African couples.
Eighty-three patients have both progenitors from the same
country of origin: Angola (n = 55), Guinea-Bissau (n = 10),
S. Tomé (n = 10), Cape Verde (n = 6), Guinea-Conakry (n =
1), and Nigeria (n = 1). Eight participants have progenitors
with different African origins (Angola/Democratic Republic
of Congo (n = 3), Angola/Cape Verde (n = 2), Angola/Guinea-
Bissau (n = 1), Cape Verde/S. Tomé (n = 1), Cape Verde/
Guinea-Bissau (n = 1)).
Data obtained from their interviews, which included demo-
graphic characteristics (age, gender, and parents’ birthplace),
were used to create a database. The database was then filled up
with data retrospectively collected from the patients’ hospital
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records regarding biochemical and hematological hemolysis
biomarkers, such as serum lactate dehydrogenase (LDH), total
bilirubin, and reticulocyte count, as well as hemoglobin pro-
filing. These parameters were obtained by standard proce-
dures, and Hb F levels were measured by high-performance
liquid chromatography (HPLC). The collected data for each
patient were the result of, at least, three different time point
analyses performed in steady state, before starting treatment
with hydroxyurea and more than 3 months after receiving a
blood transfusion. At present, 43 out of the 91 SCA patients
are under hydroxyurea treatment; however, their Hb F values
registered in the database were the ones observed previously
to HU treatment.
Cerebrovascular disease (CVD) is one of the most severe
complications in SCA, and ischemic stroke is the most severe
type of CVD, which may occur in SCA pediatric patients.
Transcranial Doppler (TCD) ultrasonography is currently the
standard tool for risk screening of stroke. Children who pres-
ent at least two measurements of time-averaged mean of the
maximum velocity (TAMMX) in the middle cerebral artery ≥
200 cm/s were classified as high risk for stroke and, usually,
entered a regular blood transfusion therapy for reducing stroke
risk. HU is another successful therapeutic option, alternatively
or in conjunction with blood transfusion therapy.
In this work, overt ischemic stroke occurrence was the
parameter used as CVD outcome. Fifteen out of the 91 en-
rolled SCA patients had already experienced at least one epi-
sode of overt ischemic stroke, confirmed by magnetic reso-
nance imaging. Four of them are currently under chronic
blood transfusion therapy. The remaining eleven entered a
chronic transfusion program in conjunction with HU
treatment.
An aliquot of peripheral blood sample was collected from
each participant for DNA extraction and candidate gene
genotyping.
The study protocol was approved by INSA’s ethics com-
mittee and is in accordance with the Helsinki declaration of
1975.
Genetic testing for known variants
Genomic DNAwas isolated from peripheral leukocytes using
the MagNA Pure LC instrument (Roche Diagnostics GmbH,
Mannheim, Germany). The homozygous status for the SCA
mutation inHBB gene (c.20A>T) was confirmed by polymer-
ase chain reaction, followed by restriction fragment length
polymorphism analysis (PCR-RFLP) with the endonuclease
Bsu36 I. Beta-globin cluster haplotypes were assigned after
examining six restriction endonucleases sites within the clus-
ter: Xmn I (5′ to HBG2), Hind III (within the HBG2 and
HBG1), Hinc II (within and 3′ to ψHBB), and Hinf I (3′ to
HBB). Aliquots of the amplified products were then digested
with the appropriate restriction enzymes under the conditions
recommended by the manufacturers. Haplotypes were in-
ferred by determining the presence or absence of cleavage at
each site, and by compiling the results into one known pattern
[27].
The 3.7-kb alpha-thalassemia deletion was assessed by
gap-PCR [28]. Concerning the two SNPs analyzed in the
BCL11A gene, rs11886868 and rs4671393, the former was
characterized by PCR-RFLP using the Mbo II endonuclease,
while the latter was analyzed by PCR followed by Sanger
sequencing in a 3130XL Genetic Analyser, ABI PRISM
(Applied Biosystems, Foster City, CA, USA). All genotype
distributions were tested positively for adherence to the
Hardy-Weinberg equilibrium.
Screening for KLF1 variants by NGS
KLF1 gene analysis was carried out by next-generation se-
quencing (NGS) of a long PCR fragment (3.2 kb) including
the KLF1 gene and its flanking regions. PCR was obtained by
using the primers: Fw5′-CTGATAGCAGCCTCCAACGT
CTGGG-3′ and Rv5′-ACCTTCAGGAGCCGCTTTCT-3′
and the FailSafe PCR enzyme with the PreMix D
(Epicentre, Illumina). PCR conditions consisted of 94 °C for
2 min, followed by 35 cycles of 94 °C for 45 s, 63 °C for 45 s,
and 72 °C for 4 min. This was followed by incubation at 72 °C
for 5 min.
NGS workflow consisted of five steps: (1) PCR product
purification using Agencourt AMPure XP (Beckman
Coulter); (2) double-stranded DNA quantification in Qubit
fluorometer (Thermo Fisher Scientific); (3) library preparation
using theNexteraXTDNALibrary Preparation Kit (Illumina)
following manufacturer’s instructions; (4) sequencing on a
MiSeq benchtop sequencer (Illumina); and (5) data analysis
using MiSeq Reporter v2.6.2 (Illumina). Variants were
inspected and validated using the Integrative Genomics
Viewer v2.3.86 [29]. KLF1 variants found by NGS were con-
firmed by Sanger sequencing.
To further assess the effect of the novel KLF1 missense
variant on protein function, bioinformatic tools were used:
SIFT (http://sift.jcvi.org) and PolyPhen-2 (http://genetics.
bwh.harvard.edu/pph2).
Statistical analysis
Statistical analyses were performed using the SPSS version 23
software. Normal distribution was assessed using
Kolmogorov-Smirnov test. Continuous variables were evalu-
ated as mean ± SD when the distribution was normal and
median with interquartile range when the distribution was
not normal. The analysis of Student’s t test was used to com-
pare differences among means and Mann-Whitney test was
used as non-parametric test of significance. A p value of <
0.05 was considered statistically significant.
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Results
Genotyping was performed to (i) confirm homozygosity for
the c.20A>T mutation in the HBB gene; (ii) identify beta-
globin cluster haplotypes and the presence of the 3.7-kb
alpha-thalassemia deletion; (iii) characterize SNPs in the
HBG2 rs7482144, BCL11A rs11886868, and rs4671393; and
(iv) search forKLF1 variants. The effect of genetic variants on
levels of Hb F, biochemical parameters related to the severity
of hemolysis, and stroke occurrence was also investigated.
Relationship between Hb F level, biochemical
parameters related to chronic hemolysis severity,
and stroke occurrence
The Hb F is known as the principal SCA genetic modifier, and
a concentration of at least 10% in SCA patients was reported as
necessary to reduce the clinical severity [30]. The Hb Fmean ±
SD presented by our SCA patients was 8.9 ± 6.4% (median
7.4%, interquartile range 9.2). Using a cut-off value of 10%,
patients with Hb F levels lower than this value were catego-
rized in the class of “lowHb F,”while those with values ≥ 10%
were grouped in the class “high Hb F.” Comparing the levels
of hemolysis-related biomarkers between these two subgroups,
the higher Hb F group presented a trend to lower values of two
of these parameters, although not reaching statistical signifi-
cance (reticulocyte count mean, 10.17 ± 4.47% vs 11.36 ±
4.93%, p = 0.271; and LDH mean 689.96 ± 324.73 U/L vs
853.35 ± 366.93 U/L; p = 0.053, respectively). On the other
hand, the group of patients who had suffered at least one stroke
event presented a significantly lower level of Hb F (Hb Fmean
5.34 ± 4.57% vs 9.36 ± 6.48%, respectively; p = 0.024).
Relationship between common polymorphisms
in (alpha and beta) globin clusters and BCL11A, Hb F
level and biochemical parameters related
to hemolysis severity, and stroke occurrence
The beta-globin cluster haplotypes found in our patients were
consistent with parental geographic origin. Taking into con-
sideration the three most representative geographic sub-
groups, they presented the following allele frequencies: (i)
the Angolan group (n = 55): Bantu 91.8%, Benin 4.5%,
Senegal 1.8%, and atypical 1.8%; (ii) the Guinean group
(n = 10): Benin 10% and Senegal 90%, and (iii) the
Santomean group (n = 10): Bantu 30%, Benin 65%, and atyp-
ical 5%. Considering genotypes, 50 patients were homozy-
gous for the Bantu haplotype, 12 were homozygous for the
Senegal haplotype, 7 were homozygous for the Benin haplo-
type, and the remaining 22 individuals were compound
heterozygotes.
We observed that patients homozygous for the Bantu hap-
lotype (n = 46) had lower Hb F (mean of 7.2 ± 4.9%) than the
homozygous for the Senegal haplotype (n = 11) who had a Hb
F mean of 12.8 ± 5.8% (p = 0.005). One fundamental differ-
ence between these two haplotypes is the SNP rs7482144
located at −158 of HBG2, where the allele A is detected as
positive. In our patients, a frequency of 18.7% of the A allele
was found, always in association with the Senegal haplotype.
It was found largely in children whose parents originated from
Cape Verde and Guinea-Bissau. The group of children pre-
senting at least one allele A (GA+AA; dominant model of
inheritance) had higher Hb F in contrast with the GG group
(11.5 ± 6.35% vs 8.08 ± 6.25%; p = 0.019) (Table 1).
Conversely, SCA patients belonging to the “high Hb F” group
were three times more likely to present the rs7482144_allele
A than those belonging to the “low Hb F” group (odds ratio =
3.0435; 95%CI = 1.1771–7.8692; p = 0.022).
Due to the African ancestry of our SCA patients, a high
prevalence of alpha-thalassemia determinants was expected
and confirmed. Fifty patients presented the normal four α-
globin genes (αα/αα), thirty-one were heterozygous for the
deletion (−α3.7kb/αα), six were homozygous (−α3.7kb/−α3.7kb),
one had the triple α-globin gene (αααanti3.7kb/αα), and for the
remaining three, no laboratory result was obtained. Thus, in
our series, 37 out of 88 patients had an alpha-thalassemia de-
terminant, corresponding to a prevalence of 42%, and an allele
frequency of the −α3.7-kb deletion of 24.4%. However, con-
sidering only the larger subgroup of Angolan SCA patients, 24
out of these 55 patients presented alpha-thalassemia, corre-
sponding to a higher prevalence of 45.5% and an allele fre-
quency of the −α3.7kb deletion of 27.3%.
We observed that the SCA patients who presented at least
one alpha-thalassemia allele (genotypes: −α3.7kb/αα or
−α3.7kb/−α3.7kb; n = 37) had a lower reticulocyte percentage
than the other group without alpha-thalassemia (genotypes:
αα/αα or ααα/αα; n = 51). The first group presented a
reticulocyte count mean of 8.61 ± 3.58% while the latter
presented 12.85 ± 4.71% (p < 0.001). Considering the retic-
ulocyte count in absolute values, the same conclusion was
obtained: the first group having alpha-thalassemia present-
ed a mean of 268,244 ± 98,453 cells/μL while the group
without alpha-thalassemia had 358,243 ± 154,259 cells/μL
(p = 0.002). Therefore, the co-inheritance of at least one
alpha-thalassemia allele seems to improve the hemolytic
status of SCA.
Concerning BCL11A SNPs, we observed a minor allele
frequency of the rs11886868_C allele of 25.8% and the
rs4671393_A allele of 27.5%. The presence of these alleles,
considering the inheritance dominant model, seems to intro-
duce a considerable increase on Hb F level (p = 0.026 and p =
0.028, respectively) (Table 1).
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Searching for genetic variants in the KLF1 gene
and their relationship with Hb F level
To investigate any possible relationship between KLF1 vari-
ants, Hb F level, and stroke occurrence in SCA, we conducted
aKLF1 gene analysis byNGS. Twelve different variants in the
KLF1 gene orin its regulatory regions were identified byNGS
and validated by Sanger sequencing (Table 2). Seventy-three
patients (80.2%) presented, at least, one variant in the KLF1
gene. However, almost all consist of alterations previously
reported as belonging to functional class 1, which comprises
those with no or minor functional consequences [16]. Six
variants were considered as common SNPs with minor allele
frequency (MAF) ≥ 5%: (i) one is located at the 5′UTR,
c.−251C>G; (ii) three are located at exon 2 and are missense
variants, c.115A>C, c.304 T > C, and c.544 T > C; and (iii)
two are located at the 3′UTR, c.*277C>T and c.*296G>A.
The most frequent variant found was the rs2072597,
c.304T>C, with a MAF of 42.86%. It is responsible for an
amino acid change in the N-terminal domain of the protein
p.(Ser102Pro). However, this change was predicted as benign
in terms of function by in silico analysis. The same result is
observed in ClinVar. The second most frequent variant found
was the rs3817621, c.−251C>G, with aMAF of the C allele of
18.68%. These two SNPs, besides being the most frequent in
our series, are reported in the 1000 Genomes Project Phase 3
as widely dispersed in the worldwide population, including
populations in the African continent where their MAFs are
44% and 19%, respectively.
In this study, two novel KLF1 variants were detected, both
in the heterozygous state, in two patients: the c. −149(C/−)
located in the promoter region, and the c.1026G>C, in exon 3
(Fig. 1). The first is a deletion of one nucleotide within an Sp1
binding site and probably affects the binding of this transcrip-
tion factor. It was found in compound heterozygosity with two
other KLF1 variants, the c.115A>C and c.304T>C, in an
Angolan patient with 3.4% of Hb F. This patient did not have
the other Hb F–related variants at HBG2 and BCL11A. The
other novel variant found in KLF1 changes the corresponding
amino acid, p.(Gln342His), that is located in the DNA-
binding domain zinc finger 3 of the KLF1 protein. However,
in silico analysis of this variant predicted a benign conse-
quence at the protein level (Polyphen: HumDiv score =
0.013 and HumVar score = 0.063; Sorting Intolerant from
Tolerant (SIFT) = 1.000). It was found in compound hetero-
zygosity with another variant of KLF1, the c.304T>C, in a
patient from Guinea-Bissau with 14.6% of Hb F. However,
it was also observed that this patient was homozygous for the
A allele at rs7482144 in the HBG2 gene, which may justify
this phenotype. Thus, in general, we found no association
between the presence of KLF1 variants and the level of Hb
F or serum hemolytic parameters or stroke events.
Discussion
Several studies have been conducted to find the main risk and
protective factors involved in the development of specific
SCA subphenotypes. Among those factors, Hb F level has
been of great interest due to its substantial protective effect
on the course (timing and severity) of SCA subphenotypes. In
our study, SCA children of sub-Saharan African couples
(mainly Angola, Guinea-Bissau, S. Tomé, or Cape Verde)
were evaluated. Their genetic background is African; howev-
er, some of these patients were born and live in Portugal. This
means that their environmental and to a certain extent their
behavioral determinants of health are southern European.
We evaluated the influence of genetic factors onHb F level,
on the level of the biochemical parameters related to hemoly-
sis, and the occurrence of overt ischemic stroke. The partici-
pants in this study showed a mean level of Hb F of 8.9 ± 6.4%
which is similar to values reported by other studies on African
SCA children, e.g., from Nigeria, Uganda, or Congo
Republic, who presented 9.9 ± 6.0% [31], 9.0 ± 5.6% [32],
and 8.8 ± 5.8% [33], respectively. Nevertheless, in other stud-
ies, lower values of Hb F have been reported for African SCA
Table 1 Comparison of Hb F levels between genotypes
Locus Variant ID MAF (allele) Genotypes n HbF (%) p value
Mean ± SD Median Inter-quartile range




















































MAF, minor allele frequency; n, number of patients
*Patients with the −α3.7kb deletion in homozygous or heterozygous status
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populations [34–37]. This discrepancy may be the result of
several factors, such as the method used for the Hb F estima-
tion, the age of the SCA patients, or due to environmental,
cellular, and genetic factor modulators of phenotypic expres-
sion of Hb F.
A level of Hb F above 10% has been suggested as neces-
sary for reduced SCA clinical severity [30]. Accordingly, we
have found a negative association between the occurrence of
ischemic stroke and the level of Hb F. In fact, SCA patients
who have experienced stroke presented significantly lower
values of mean Hb F in contrast to the group without stroke
(Hb F mean 5.34 ± 4.57% vs 9.36 ± 6.48%, respectively; p =
0.024). Other authors, when studying Nigerian SCA patients,
obtained similar results: the group presenting stroke had a
mean of Hb F level of 5.6 ± 1.5% in contrast to the group
without stroke, which presented Hb F of 10.0 ± 6.1% [31].
Besides the role of Hb F in modulating SCA morbidity, the
co-inheritance of alpha-thalassemia has also been considered
an important genetic modulator. It seems to play a role in
reducing the intensity of chronic hemolysis by decreasing
the tendency of deoxy Hb S to polymerize through lowering
the mean cell hemoglobin concentration and erythrocyte den-
sity [5, 38]. Moreover, the damaging role of hemolysis is
evident in the pathophysiology of SCA since free hemoglobin
is a well-known scavenger of nitric oxide, which maintains
vascular patency through a cascade of biological events that
culminate in the relaxation of smooth muscle cells of blood
vessel walls. Our findings are in line with this theory, as we
found a significant association between the presence of alpha-
thalassemia and decreased reticulocyte count, one of the he-
molysis biomarkers analyzed. Thus, the co-inheritance of
alpha-thalassemia with SCA seems to act beneficially in two













Functional prediction of aa change
SIFT** PolyPhen-2***
12887540 rs78874830C>T promoter c.-400C>T 0.011 (A) n.a.
12887391 rs3817621G>C promoter c.-251C>G 0.187 (C) n.a.
12887289 rs974504807delG promoter c.-149 (C/-) 0.005 (delG) n.a.
12886919 rs10407416C>G Intron 1 c.87+135G>C 0.022 (G) n.a.
12886115 rs112631212T>G Exon 2 c.115A>C 0.066 (G) p.(Met39Leu) Tolerated
1.000
Benign 0.000
12885926 rs2072597A>G Exon 2 c.304T>C 0.429 (G) p.(Ser102Pro) Tolerated
0.283
Benign 0.000




12885282 rs115339342C>T Intron 2 c.913+35G>A 0.010 (T) n.a.
12884948 rs146658904C>G Exon 3 c.1026G>C 0.005 (G) p.(Gln342His) Tolerated
1.000
Benign 0.013
12884775 rs185829666G>A 3’UTR c.*110C>T 0.005 (A) n.a.
12884608 rs16978757G>A 3’UTR c.*277C>T 0.159 (A) n.a.
12884589 rs16978754C>T 3’UTR c.*296G>A 0.165 (T) n.a.
MAF= minor allele frequency; aa= amino acid
*Chromosome position was obtained from Genome Reference Consortium Human Build 38 patches release 12 (GRCh38.p12)
**SIFT scores range from 0.000 to 1.000 and amino acid change is predicted as damaging if the score is ≤0.050, and tolerated if it is >0.050





Fig. 1 DNA sequencing showing
the two novel variants in the
KLF1 gene (minus strand),
detected in heterozygosity in two
SCA patients. a Located in the
promoter, c.−149(C/−). b Located
in exon 3, c.1026G>C
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ways: by lowering reticulocyte count and consequently their
harmful adhesion to endothelium and by decreasing the sever-
ity of hemolysis, and consequently free hemoglobin levels,
which in turn preserves the protective effect of higher nitric
oxide bioavailability.
Our results confirm the importance of HBG2 and BCL11A
loci in the regulation of Hb F expression in sub-Saharan
African SCA descents. On the other hand, our results did not
show an association between the presence of KLF1 variants
and levels of Hb F, serum hemolytic parameters, or stroke
events. This fact may be due to the nature of theKLF1 variants
found in this population, which is consistent with the absence
of functional consequences, as predicted by in silico analysis.
The KLF1 protein contains at its C-terminal region three
zinc finger domains that enable its binding to DNA at specific
sites of the genome, in order to control gene expression by
working primarily as a transcriptional activator. Genetic vari-
ants located at critical residues of those zinc finger domains
have functional consequences and are classified as belonging
to functional classes 2 to 4 [16]. On the other hand, variants
located outside those DNA-binding domains are categorized
in class 1, since they present minor or no functional conse-
quences [16]. It is expected that KLF1 variants belonging to
classes 2 or 3 are associated with reduced levels of KLF1
factor (and consequently of the HBG repressor BCL11A),
originating derepression of the fetal globin genes and conse-
quently increased Hb F levels [17, 18]. This is in line with
some studies where KLF1 classes 2 and 3 variants were ob-
served at high frequency in populations where thalassemias
are endemic and where they were associated with high Hb F
levels and/or with thalassemia milder phenotypes, e.g., in
Southern China [19, 39], South East Asia [20, 21], and
Sardinia [40]. However, SCA presents a different worldwide
distribution, with a high prevalence in African and Arab-
Indian populations. In those populations, the prevalence of
KLF1 variants and their possible association with Hb F levels
have been poorly investigated. Two genome-wide association
studies performed in SCA patients of African descent failed to
identify common KLF1 variants influencing F-cell count [41]
or associated with higher Hb F levels [25]. Another study
addressed the hypothesis of loss-of-function mutations in
KLF1 being involved with increased Hb F levels in SCA
patients of diverse origins residing in the UK. This investiga-
tion concluded that only one (Nigerian) patient out of the 55
SCA patients studied presented a KLF1 mutation and in-
creased Hb F [26]. Similarly, research on 44 SCA patients
with high Hb F levels and an Arab-Indian origin (presenting
the Arab-Indian haplotype in the beta-globin cluster) did not
find the variants in the KLF1 zinc finger domains that were
previously associated with increased Hb F. Therefore, the au-
thors concluded that the KLF1 SNPs detected were neutral in
determining Hb F level in those patients [22]. Our study dem-
onstrates that variants in KLF1 are prevalent in sub-Saharan
populations with SCA (≈ 80% of the patients present at least
one variant in this gene). However, due to their non-
deleterious effect on gene expression (mainly class 1 variants),
they do not show association with any peculiar subphenotype
and do not seem to be a relevant modifier of Hb F expression.
On the other hand, rare variants located at specific sites
of the KLF1 promoter may disturb the normal gene tran-
scription level. This is the case of the reported c.−148G>A
variant for which in vitro studies revealed a consequent
ablation of the SP1 transcription factor binding and a re-
duction of KLF1 expression [42]. Similarly, we found a
nearby novel heterozygous single nucleotide deletion
c.−149(C/−), in a SCA Angolan patient presenting with a
mean Hb F of 3.4% and absence of the high Hb F–related
alleles at HBG2 or BCL11A. This variant may negatively
affect the SP1 binding, consequently reducing KLF1 ex-
pression in this individual but, due to its low frequency in
the studied population (1/182 alleles), we can conclude
that its impact in sub-Saharan SCA patients’ Hb F level
is not relevant.
Three previously reported KLF1 missense variants,
p.(Met39Leu), p.(Ser102Pro), and p.(Phe182Leu), were
found in this study. The most frequent of them, the
p.(Ser102Pro), was observed with a remarkably high al-
lele frequency (42.9%). Its widely dispersed geographical
distribution is known, with a minor allele frequency >
40% [43]. In an early study, this variant in homozygosity
showed a 15% reduction in KLF1 expression, when com-
pared with the normal wild-type genotype [42].
Nevertheless, similarly to our study, other authors did
not find an association of this variant with any peculiar
subphenotype [44]. The other two frequent missense var-
iants we found, the p. (Met39Leu) and p.(Phe182Leu),
showed allele frequencies of 6.6 and 4.9%, respectively,
which is in accordance with published data for the
African population in the “1000 Genomes Project.”
Regarding the novel missense variant located in KLF1 ex-
on 3, the c.1026G>C, p.(Gln342His), in silico analysis indi-
cates it probably will have no effect on KLF1 function. In our
study, it was found in heterozygosity in only one SCA patient,
a child of a Guinea-Bissau couple. This patient had a high
mean Hb F (14.6%). However, this may be just a coincidental
finding, as he also presented homozygosity for the A allele at
SNP rs7482144, the −158 Xmn I site of HBG2, which per se
may account for the observed high Hb F phenotype.
Conclusion
We conclude that higher Hb F levels have an inverse relation-
ship with sub-Saharan SCA disease burden, namely on the
most severe vascular outcome in children—the occurrence
of ischemic stroke. In addition, there is a significant effect of
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alpha-thalassemia co-inheritance in the intensity of chronic
hemolysis in these patients. These genetic factors have the
potential to be used as early prognosis biomarkers, suggesting
a closer follow-up and prioritizing access to Hb F–inducing
pharmacological agents. We also conclude that, although
some genetic modification of KLF1 expression may result in
increased Hb F levels, and consequently in ameliorating dis-
ease phenotype, the low prevalence of functional KLF1 vari-
ants in the sub-Saharan background seems to be non-
significant in the SCA clinical modulation context.
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